<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.00pm</td>
<td>Registration opens – Plaza Level</td>
</tr>
<tr>
<td>8.30am–10.30am</td>
<td>Symposium: Innovations in program design for sexual and reproductive health (BCEC – Room P1, Plaza Level) Chairs: Sevgi Aral &amp; James Blanchard</td>
</tr>
<tr>
<td>9.00am–9.30am</td>
<td>Enhancing program efficiency of voluntary medical male circumcision for HIV prevention: A novel modelling approach. Suzanne Awad</td>
</tr>
<tr>
<td>9.30am–10.00am</td>
<td>Achieving maximal health impact with available resources: balancing the science, economics, and politics of HIV. Cliff Kerr</td>
</tr>
<tr>
<td>10.00am–10.30am</td>
<td>Optimizing HIV management strategies through an integrated quantitative/mathematical framework. Babak Pourbohlouli</td>
</tr>
<tr>
<td>10.30am–11.00am</td>
<td>MSM Program in Ghana – successful new approaches to improve coverage. Nana Clement</td>
</tr>
<tr>
<td>11.00am–11.30am</td>
<td>Morning Tea in Foyer P1</td>
</tr>
<tr>
<td>11.00am–12.30pm</td>
<td>Symposium: Innovations in program design for sexual and reproductive health (Room P1, Plaza Level) Chairs: Sevgi Aral &amp; James Blanchard</td>
</tr>
<tr>
<td>11.00am–11.30am</td>
<td>Adolescent Linkage to STD/HIV Prevention: The role of partnerships, targeting, and tailoring. Patricia Dittus</td>
</tr>
<tr>
<td>11.30am–12.00pm</td>
<td>Assessing programme impact through multiple non-experimental methods: The case of chlamydia screening in England and other stories. Anne Johnson</td>
</tr>
<tr>
<td>12.00pm–12.30pm</td>
<td>Improving quality and efficiency within the English National Chlamydia Screening Programme: using a program science approach to develop a quality care pathway. John Saunders</td>
</tr>
<tr>
<td>12.30pm–1.30pm</td>
<td>Lunch in Foyer P1</td>
</tr>
<tr>
<td>1.30pm–3.00pm</td>
<td>Symposium: Innovations in program design for sexual and reproductive health – Epidemiology Room: P1, Plaza Level Chairs: Sevgi Aral &amp; James Blanchard</td>
</tr>
<tr>
<td>1.30pm–3.00pm</td>
<td>A strategy for HIV/STI prevention in low and middle income countries (Bill and Melinda Gates Foundation) Room: M3 Mezzanine Chairs: Gina Dallabetta &amp; Saul Johnson</td>
</tr>
<tr>
<td>1.30pm–2.00pm</td>
<td>Spatial epidemiology of HIV Infection in sub-Saharan Africa: A methodology for identifying populations at high risk of HIV infection in sub-Saharan Africa. Diego Cuadros</td>
</tr>
<tr>
<td>1.30pm–1.45pm</td>
<td>HIV and STI Prevention: What is an Intervention? James Hargreaves S01.1</td>
</tr>
<tr>
<td>1.45pm–2.00pm</td>
<td>Systematic reviews of the efficacy and effectiveness of biological, behavioral and structural HIV prevention interventions. S01.2 Shani Krishnaatne</td>
</tr>
<tr>
<td>1.30pm–2.00pm</td>
<td>Education about Sex and Relationships: New directions in school and beyond (ASHA) Rooms: M1&amp;2 Mezzanine Chairs: Jayne Lucke &amp; Sarah Hawkes S02.1</td>
</tr>
<tr>
<td>2.00pm–2.15pm</td>
<td>Sex and relationships education in schools: A key component of sexual health promotion. Peter Aggleton S02.2</td>
</tr>
<tr>
<td>2.15pm–2.30pm</td>
<td>Religious and faith-based beliefs: A help or a hindrance in sexual health education? Mary Lou Rasmussen S02.2</td>
</tr>
</tbody>
</table>
SUNDAY 13 SEPTEMBER

09.00am–12.00noon: Plenary: Taking stock of the global health threats in the broad field of STIs and HIV: Africa. State of the epidemic and epidemic prevention.

1.00pm–2.30pm: Plenary session 1 – stage 1 – Great Hall 2 – Door 8 – Mezzanine

2.30pm–3.30pm: Plenary session 1 – stage 2 – Great Hall 2 – Door 8 – Mezzanine

3.30pm–4.30pm: Plenary session 1 – stage 3 – Great Hall 2 – Door 8 – Mezzanine

4.30pm–5.30pm: Plenary session 1 – stage 4 – Great Hall 2 – Door 8 – Mezzanine

5.30pm–6.30pm: Plenary session 1 – stage 5 – Great Hall 2 – Door 8 – Mezzanine

MONDAY 14 SEPTEMBER

09.00am–10.15am: Plenary Session 1 – Great Hall 4 – Door 1 Foyer

11.15am–12.15pm: Plenary Session 1 – Great Hall 4 – Door 1 Foyer

12.30pm–1.15pm: Plenary Session 1 – Great Hall 4 – Door 1 Foyer

1.15pm–2.45pm: Symposium Y01

2.45pm–3.45pm: Symposium Y01

3.45pm–4.25pm: Symposium Y01

4.25pm–5.05pm: Symposium Y01

5.05pm–5.45pm: Symposium Y01

5.45pm–6.25pm: Symposium Y01

6.25pm–7.05pm: Symposium Y01

7.05pm–8.05pm: Symposium Y01

8.05pm–9.05pm: Symposium Y01
**Monday 14 September**

**Special Presentation**

*Remote settings.*

**Session O01.6**

**Exploring the benefits of remote surveillance in molecular testing for gonorrhoeae resistance surveillance in China**, with Ella Trembizki (ISSTDR Scholarship).

**Session O02.1**

**Recent Rise in Reduced Susceptibility to Ceftriaxone In Neisseria gonorrhoeae: Two Treponemal Tests for Syphilis Useful in China**, with Dong Jin Shin (ISSTDR Scholarship).

**Session O02.3**

**The Prevalence of Molecular-Based Surveillance in Neisseria gonorrhoeae as part of Standardized National Sentinel Laboratories for Gonorrhoea in Nigeria**, with Yetunde Fakila (ISSTDR Scholarship).

**Session O02.5**


**Session O03.1**

**Multimodal (GC) and Chlamydia (CT) Tests for Chlamydia trachomatis of urogenital populations are variants of a New Molecular-Based Platform for Non-Invasive Diagnosis**, with Matthew Golden (GC) and Samuel Turner (ISSTDR Scholarship).

**Session O03.4**

**The Influence of Sexual Health Status Amongst Young Virgin Brides: Adolescent Girls’ in a Collect Study**, with Loyd Brendan P. Norella (GC) and Christine Johnston (GC).

**Session O04.1**

**The Role of HPV as an Indication of Genital Ulcer Disorder in Women Living With HIV in rural India.**, with Jonathan Ross (ISSTDR Scholarship).

**Session O04.2**

**How far violation of bodily rights in relation to STI treatment failure and HIV therapy: new and old vaccines as Adjunctive Therapy**, with Andrew Grulich (ISSTDR Scholarship).

**Session O04.3**

**The Role of Sexual Health Information in the Introduction of Govt. Family Planning Services: Influence of Technology: Influences of Technology, Possibilities and Opportunities.**, with Jane Tomnay (ISSTDR Scholarship).

**Session O04.4**

**Overlapping HIV and sex discrimination study to the Novel Spiropyrimidine (HPV) Biomarkers Help Can Human Papillomavirus outcomes among MSM**, with Peter Timms (ISSTDR Scholarship).

**Session O05.1**

**Molecular assay for Multiplex assay for Detecting Resistance Melting Analysis for Neisseria gonorrhoeae.**, with Fengyi Jin (ISSTDR Scholarship).

**Session O06.1**

**Moving forward. The global roadmap for vaccine development: Pipeline moving forward.**, with Brad Stoner & Paulina Milner (GC).

**Session O06.2**

**Detection of Human Papillomavirus in Clinical Practice: Moving Forward.**, with John A. Eggert (ISSTDR Scholarship).

**Session O06.3**

**Chlamydia trachomatis is a key cephalosporin resistance mechanism.**, with Vicky Jespers (ISSTDR Scholarship).

**Session O07.1**

**The high prevalence of urogenital Mycoplasma genitalium in South East Asia Island Countries – Initial Findings in a cross sectional study.**, with Peter Timms (ISSTDR Scholarship).

**Session O07.2**

**The global agenda (WHO) and HIV rights in relation to STI and HIV**, with Peter Timms (ISSTDR Scholarship).

**Session O07.3**

**How far violation of bodily rights in relation to STI treatment failure and HIV therapy: new and old vaccines as Adjunctive Therapy**, with Andrew Grulich (ISSTDR Scholarship).

**Session O07.4**

**Better, sooner, more youth friendliness of reproductive health information? A Friend? Where do young men get their sexual health information?**, with Megan Lim (ISSTDR Scholarship).
Falling between the gaps: an overview of issues for Aboriginal and Torres Strait Islander women who want to be sexually healthy.

Panel Discussion
Dr. Rebecca Guy
Kirby Institute, Sydney, Australia

Setting, Use of Molecular Point–of–Care Tests to Reduce Sexually Transmissible Infections in a High Burden Setting,
Westminster NHS Trust, UK

Live Demonstration: Rapid STI Screening with Xpert® CT/NG*, Dean Street Express: An Innovative Service, Alabama at Birmingham, USA

New CDC Guidelines and the Emerging Need for Rapid CT/NG Testing,
Prof. Edward Hook
University of Alabama at Birmingham, USA

It's all about optimising patient care
The Use of Rapid Diagnostics to Transform the Management of STDs

Figures are present in the image, including schedules and locations such as "Great Hall 4 – Door 1 Foyer" and "Exhibition Hall 1". The text also mentions topics like "Neisseria gonorrhoeae" and "Mycoplasma genitalium". It includes keywords like "plenary session", "afternoon tea and poster viewing", and "screening for chlamydia: does it work, results from a CCept pilot study".

The document contains elements of a conference program with specific times and locations, indicating a structured agenda for the event. It appears to focus on health, particularly sexual health, with sessions discussing the impact on Aboriginal and Torres Strait Islander women.
TUESDAY 15 SEPTEMBER

12.30pm–2.00pm

1.30pm–12.30pm

12.15pm

tueSday 15 September

aStda Luncheon – plaza terrace room, plaza Level

Lunch and Poster Viewing in Exhibition Hall 1

Young Investigator Award: Robert Kirkcaldy, MD, MPH

Distinguished Career Award: Anna Wald, MD, MPH

(ISSTDR Scholarship)

from the Patient Sample.

Genome Sequencing Directly

O09.5

Novel Custom Genotyp-

Superinfection using a

subtypes.

O9.3

Scholarship).

antimicrobial agents against

gonorrhea mouse model

Establishment of the

O09.2

12.15pm–12.00pm–

12.00pm–11.45am–

11.45am–11.30am–

Dependent AmpliVue Assay.

Trichomonas vaginalis

Rapid Diagnosis of

Charlotte Gaydos

Trichomonas vaginalis

and Neisseria gonorrhoeae,

of swabs for the detection

O10.4

(ISSTDR Scholarshiip)

partner circumcision.

association with male

and cofactors among

S11.3

Bacterial Biofilm on

is Associated with Stability

Organisms.

The Broad Diversity of

Jørgen Jensen

Anna Wald &

Door 6 Mezzanine

Room: Great Hall 1 –

Vaginal health and the

Pregnant Women and the

Understanding the

Door 8 Mezzanine

Room: M1&2 –

The prevalence of

Aged 15-19 years old

Health Care Attendance

O16.5

S12.1

New Zealand

Sexual health issues for

Andrew Vallely &

Mental health services to address

Health services for children

from At RISK and Beyond:

From At RISK and Beyond:

From At RISK and Beyond:

2.30pm–2.15pm–

2.25pm–2.20pm–

2.00pm–

2.00pm–

2.40pm–

2.55pm–

2.40pm–

2.15pm–

2.00pm–

S11

S11.1

S11.2

S11.3

S09.4

S10.3

S12

S13

S14

S15

S16

S17

S18

S19

S20

S21

S22

S23

S24

S25

S26

S27

### Tuesday 15 September

#### 8.00am – 12.00pm

**Chair:**
Dr Henry J C de Vries, Professor of Skin Infections, STI outpatient clinic, Public Health Service Amsterdam, Department of Dermatology, and CINIMA, Academic Medical Center, University of Amsterdam, and Centre for Infectious Sexually transmitted infections in men who have sex with men.

**Topics:**
- Diseases Control, National Institute for Public Health and the Environment (CIb/RIVM), Bilthoven, The Netherlands
- Where are the men? STI and sexual health services for men.
- Male circumcision for STI prevention – how well does it work and how is it done?

#### 12.00pm – 3.00pm

**Afternoon Tea and Poster Viewing in Exhibition Hall 1**

#### 3.00pm – 5.30pm

**Topics:**
- Cervicovaginal microbiome.
- Dietary Intake and Dysbiotic Association Between..
- Impact of The LNG-IUS on Cervical Persistence of Cervical persistence of Chlamydia trachomatis.
- The Natural History of Infection in Women: A Multi-Parameter Evidence Synthesis.
- Impact of The LNG-IUS on Cervical Persistence of Cervical persistence of Chlamydia trachomatis.
- The Many Facets of the Vaginal Microbiome in Health and Disease.
- The Vaginal Microbiome and STI.
- The Microbiome in Women: Persistent and Vaginal Microbiota in Chlamydia trachomatis cervical Persistence of.
- The Natural History of Infection in Women: A Multi-Parameter Evidence Synthesis.

#### 5.30pm – 8.00pm

**Panel discussion on PrEP in Australia and Queensland 2015**

**Speakers:**
- Professor Bob Grant
- Dr Darren Russell
- Dr Fiona Bisshop
- Mr Heath Payner
- Chris Williams

**Topics:**
- Hear how PrEP has changed HIV in San Francisco from the man who led the way.
- What is it like to be on PrEP?
- Nonavalent HPV Vaccination and Cost-Effectiveness of HPV vaccine introduction in Thailand.
- HPV vaccine introduction in Thailand.
- HPV vaccine introduction in Thailand.
- HPV vaccine introduction in Thailand.
- HPV vaccine introduction in Thailand.
- HPV vaccine introduction in Thailand.

#### 8.00pm – 12.00am

**Plenary Session Community FNP Forum by the HIV Foundation QLD**

**Topics:**
- Moderated Panel:
- Q&A
- Your questions answered – Panel.

**Speakers:**
- Dr Darren Russell
- Dr Fiona Bisshop
- Mr Heath Payner
- Chris Williams

**Topics:**
- PrEP in Australia and Queensland 2015
- Your questions answered – Panel
- What is it like to be on PrEP?
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.15am–</td>
<td>Characterizing Cale‐quinolone Excretion in HIV-1 negative and Positive Subjects: Ireland</td>
<td>John Zaunders</td>
</tr>
<tr>
<td>11.30am–</td>
<td>HIV-1 sequence diversity and Its Impact: The Megamodel Look</td>
<td>Perumal Chelliah</td>
</tr>
<tr>
<td>11.45am–</td>
<td>The mechanism of reactivation of the reservoir: the role of chemokine ligand signaling</td>
<td>Ian England, Brandi Adkins, Francis Ferrero</td>
</tr>
<tr>
<td>12.00pm–</td>
<td>Understanding the HIV Nef Protein: Regulating Viral Replication, Entry and Infection</td>
<td>Tony Cunningham &amp;</td>
</tr>
<tr>
<td>12.15pm–</td>
<td>Preclinical and clinical development of Novel HIV Integrase Inhibitors</td>
<td>Abhilasha Mathur</td>
</tr>
<tr>
<td>12.30pm–</td>
<td>The macrophage-t lymphocyte interaction: implications for the control of HIV</td>
<td>Valliyoor Srinivasan</td>
</tr>
<tr>
<td>12.45pm–</td>
<td>The role of CD4 in maintaining a state of latency for HIV: CD4-specific and CD4-independent</td>
<td>Alvin Ziegler</td>
</tr>
<tr>
<td>1.00pm–</td>
<td>Evaluation of KX3‐101 efficacy and safety in female volunteers: Phase II study</td>
<td>Sherry Chin</td>
</tr>
<tr>
<td>1.15pm–</td>
<td>Estimation of the number of individuals in the HIV epidemic: HIV prevalence and incidence</td>
<td>William Smith &amp;</td>
</tr>
<tr>
<td>1.30pm–</td>
<td>The role of Th17 cells and IL-17 in the control of HIV: Th17 cell activation and function</td>
<td>Ingrid Hopp</td>
</tr>
<tr>
<td>1.45pm–</td>
<td>The role of Th17 cells and IL-17 in the control of HIV: Th17 cell activation and function</td>
<td>Ingrid Hopp</td>
</tr>
<tr>
<td>2.00pm–</td>
<td>The role of Th17 cells and IL-17 in the control of HIV: Th17 cell activation and function</td>
<td>Ingrid Hopp</td>
</tr>
<tr>
<td>2.15pm–</td>
<td>The role of Th17 cells and IL-17 in the control of HIV: Th17 cell activation and function</td>
<td>Ingrid Hopp</td>
</tr>
<tr>
<td>2.30pm–</td>
<td>The role of Th17 cells and IL-17 in the control of HIV: Th17 cell activation and function</td>
<td>Ingrid Hopp</td>
</tr>
<tr>
<td>2.45pm–</td>
<td>The role of Th17 cells and IL-17 in the control of HIV: Th17 cell activation and function</td>
<td>Ingrid Hopp</td>
</tr>
<tr>
<td>3.00pm–</td>
<td>The role of Th17 cells and IL-17 in the control of HIV: Th17 cell activation and function</td>
<td>Ingrid Hopp</td>
</tr>
<tr>
<td>3.15pm–</td>
<td>The role of Th17 cells and IL-17 in the control of HIV: Th17 cell activation and function</td>
<td>Ingrid Hopp</td>
</tr>
<tr>
<td>3.30pm–</td>
<td>The role of Th17 cells and IL-17 in the control of HIV: Th17 cell activation and function</td>
<td>Ingrid Hopp</td>
</tr>
<tr>
<td>3.45pm–</td>
<td>The role of Th17 cells and IL-17 in the control of HIV: Th17 cell activation and function</td>
<td>Ingrid Hopp</td>
</tr>
<tr>
<td>4.00pm–</td>
<td>The role of Th17 cells and IL-17 in the control of HIV: Th17 cell activation and function</td>
<td>Ingrid Hopp</td>
</tr>
<tr>
<td>4.15pm–</td>
<td>The role of Th17 cells and IL-17 in the control of HIV: Th17 cell activation and function</td>
<td>Ingrid Hopp</td>
</tr>
<tr>
<td>4.30pm–</td>
<td>The role of Th17 cells and IL-17 in the control of HIV: Th17 cell activation and function</td>
<td>Ingrid Hopp</td>
</tr>
<tr>
<td>4.45pm–</td>
<td>The role of Th17 cells and IL-17 in the control of HIV: Th17 cell activation and function</td>
<td>Ingrid Hopp</td>
</tr>
<tr>
<td>5.00pm–</td>
<td>The role of Th17 cells and IL-17 in the control of HIV: Th17 cell activation and function</td>
<td>Ingrid Hopp</td>
</tr>
<tr>
<td>5.15pm–</td>
<td>The role of Th17 cells and IL-17 in the control of HIV: Th17 cell activation and function</td>
<td>Ingrid Hopp</td>
</tr>
<tr>
<td>5.30pm–</td>
<td>The role of Th17 cells and IL-17 in the control of HIV: Th17 cell activation and function</td>
<td>Ingrid Hopp</td>
</tr>
<tr>
<td>5.45pm–</td>
<td>The role of Th17 cells and IL-17 in the control of HIV: Th17 cell activation and function</td>
<td>Ingrid Hopp</td>
</tr>
<tr>
<td>6.00pm–</td>
<td>The role of Th17 cells and IL-17 in the control of HIV: Th17 cell activation and function</td>
<td>Ingrid Hopp</td>
</tr>
<tr>
<td>6.15pm–</td>
<td>The role of Th17 cells and IL-17 in the control of HIV: Th17 cell activation and function</td>
<td>Ingrid Hopp</td>
</tr>
<tr>
<td>6.30pm–</td>
<td>The role of Th17 cells and IL-17 in the control of HIV: Th17 cell activation and function</td>
<td>Ingrid Hopp</td>
</tr>
<tr>
<td>Session</td>
<td>Time</td>
<td>Title</td>
</tr>
<tr>
<td>---------</td>
<td>----------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>A</td>
<td>11.00am-12.30pm</td>
<td>Biomedical update: AFAO and HIV Australia Launch: Expanded horizons for HIV treatment and prevention</td>
</tr>
<tr>
<td></td>
<td>11.30am-12.30pm</td>
<td>Using DAA therapy to eliminate HCV – reality or dream? (Theme B)</td>
</tr>
<tr>
<td></td>
<td>12.30pm-1.15pm</td>
<td>HIV-1 transmission - Lessons from heterosexual couples in Africa (Theme B)</td>
</tr>
<tr>
<td>B</td>
<td>11.00am-12.30pm</td>
<td>When to start: A broader look on ARV Guidelines (Theme C)</td>
</tr>
<tr>
<td></td>
<td>11.00am-12.30pm</td>
<td>Using DAA therapy to eliminate HCV – reality or dream? (Theme B)</td>
</tr>
<tr>
<td></td>
<td>12.30pm-1.15pm</td>
<td>HIV-1 transmission - Lessons from heterosexual couples in Africa (Theme B)</td>
</tr>
<tr>
<td>C</td>
<td>11.00am-12.30pm</td>
<td>HIV-related innate immune responses in viral patients: can the innate immune system provide insight into viral pathogenesis?</td>
</tr>
<tr>
<td></td>
<td>11.00am-12.30pm</td>
<td>Using DAA therapy to eliminate HCV – reality or dream? (Theme B)</td>
</tr>
<tr>
<td></td>
<td>12.30pm-1.15pm</td>
<td>HIV-1 transmission - Lessons from heterosexual couples in Africa (Theme B)</td>
</tr>
<tr>
<td>D</td>
<td>11.00am-12.30pm</td>
<td>HIV-related innate immune responses in viral patients: can the innate immune system provide insight into viral pathogenesis?</td>
</tr>
<tr>
<td></td>
<td>11.00am-12.30pm</td>
<td>Using DAA therapy to eliminate HCV – reality or dream? (Theme B)</td>
</tr>
<tr>
<td></td>
<td>12.30pm-1.15pm</td>
<td>HIV-1 transmission - Lessons from heterosexual couples in Africa (Theme B)</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td></td>
</tr>
<tr>
<td>------</td>
<td>-------</td>
<td></td>
</tr>
<tr>
<td>8.30pm</td>
<td>Meeting Room 1&amp; 2, Mezzanine Level</td>
<td></td>
</tr>
<tr>
<td>9.00pm</td>
<td>Chairs: Professor Darren Russell - focussing on using existing treatments as prevention; how can we make the playground safer?</td>
<td></td>
</tr>
<tr>
<td>9.15pm</td>
<td>Professor Andrew Carr - focussing on single tablet regimens and ask the question: is this regimen for a lifetime?</td>
<td></td>
</tr>
<tr>
<td>9.30pm</td>
<td>Professor Heather Worth and Larissa Heath - highlighting how innovative thinking, and application of scientific investigation might deliver outcomes beyond today’s expectations</td>
<td></td>
</tr>
<tr>
<td>10.00pm</td>
<td>Theme A - Cure/Latency/CNS</td>
<td></td>
</tr>
<tr>
<td>10.15pm</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>4.00pm</td>
<td>Room:  Great Hall 2, Door 8, Mezzanine Level</td>
<td></td>
</tr>
<tr>
<td>4.15pm</td>
<td>Theme B - Antiretroviral Therapy</td>
<td></td>
</tr>
<tr>
<td>4.30pm</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>5.00pm</td>
<td>Room:  Great Hall 3, Door 4, Foyer Level</td>
<td></td>
</tr>
<tr>
<td>5.15pm</td>
<td>Theme C - Evaluating Hyper-Efficacy</td>
<td></td>
</tr>
<tr>
<td>5.30pm</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>5.30pm</td>
<td>Theme D - The role of Targets in HAART</td>
<td></td>
</tr>
<tr>
<td>5.30pm</td>
<td>Room:  Great Hall 4, Door 1, Foyer Level</td>
<td></td>
</tr>
<tr>
<td>6.00pm</td>
<td>Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>6.15pm</td>
<td>“Getting to 90/90/90”: MSM community perspectives on getting to 90/90/90 targets in HIV policy</td>
<td></td>
</tr>
<tr>
<td>6.30pm</td>
<td>“Getting to 90/90/90” Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>8.30pm</td>
<td>Living with HIV: A Pilot of the Self-management for People infected with HIV (321)</td>
<td></td>
</tr>
<tr>
<td>9.00pm</td>
<td>Primary results of the Positive Action Against Reversal (PAART) study (351)</td>
<td></td>
</tr>
<tr>
<td>9.15pm</td>
<td>Effects of HIV Treatment Interruption on the Articular Region - results from TAHOD (074)</td>
<td></td>
</tr>
<tr>
<td>9.30pm</td>
<td>Ways of Obtaining Erectile Function Among Gay and Bisexual Men (515)</td>
<td></td>
</tr>
<tr>
<td>9.45pm</td>
<td>Gay and Bisexual Men: Retail and Street Strategies and challenges (226)</td>
<td></td>
</tr>
<tr>
<td>10.00pm</td>
<td>Improving the Treatment Cascade for Aboriginal and Torres Strait Islander People (452)</td>
<td></td>
</tr>
<tr>
<td>10.15pm</td>
<td>Improving the Treatment Cascade for Aboriginal and Torres Strait Islander People (452)</td>
<td></td>
</tr>
<tr>
<td>10.30pm</td>
<td>Improving the Treatment Cascade for Aboriginal and Torres Strait Islander People (452)</td>
<td></td>
</tr>
<tr>
<td>10.45pm</td>
<td>Improving the Treatment Cascade for Aboriginal and Torres Strait Islander People (452)</td>
<td></td>
</tr>
<tr>
<td>11.00pm</td>
<td>Improving the Treatment Cascade for Aboriginal and Torres Strait Islander People (452)</td>
<td></td>
</tr>
<tr>
<td>11.15pm</td>
<td>Improving the Treatment Cascade for Aboriginal and Torres Strait Islander People (452)</td>
<td></td>
</tr>
<tr>
<td>11.30pm</td>
<td>Improving the Treatment Cascade for Aboriginal and Torres Strait Islander People (452)</td>
<td></td>
</tr>
<tr>
<td>11.45pm</td>
<td>Improving the Treatment Cascade for Aboriginal and Torres Strait Islander People (452)</td>
<td></td>
</tr>
<tr>
<td>12.00am</td>
<td>Improving the Treatment Cascade for Aboriginal and Torres Strait Islander People (452)</td>
<td></td>
</tr>
<tr>
<td>12.15am</td>
<td>Improving the Treatment Cascade for Aboriginal and Torres Strait Islander People (452)</td>
<td></td>
</tr>
</tbody>
</table>

**Thursday, 17 September**

- **Morning Session**
  - **Venue:** Great Hall 2, Door 8, Mezzanine Level
  - **Time:** 9:00 am - 1:00 pm
  - **Theme:** Cure Latency CNS

- **Lunch Break**
  - **Venue:** Great Hall 2, Door 8, Mezzanine Level
  - **Time:** 1:00 pm - 2:00 pm

- **Afternoon Session**
  - **Venue:** Great Hall 2, Door 8, Mezzanine Level
  - **Time:** 2:00 pm - 7:30 pm

**Thursday, 17 September**

- **Morning Session**
  - **Venue:** Great Hall 2, Door 8, Mezzanine Level
  - **Time:** 9:00 am - 1:00 pm
  - **Theme:** Cure Latency CNS

- **Lunch Break**
  - **Venue:** Great Hall 2, Door 8, Mezzanine Level
  - **Time:** 1:00 pm - 2:00 pm

- **Afternoon Session**
  - **Venue:** Great Hall 2, Door 8, Mezzanine Level
  - **Time:** 2:00 pm - 7:30 pm
FRIDAY 16 SEPTEMBER

Morning Tea and Poster Viewing in Exhibition Hall 1

10:30am – 12:00pm

Posters – Theme B: Facilitator: John McBride

Poster No. 10-  Impact of a Pharmacist Review during Annual Health Checks in HIV patients taking combination antiretroviral therapy - Ivette Aguirre

Poster No. 25 - PLHIV self assessment tool  for recognising signs and symptoms of HIV cognitive impairment - Denise Cummins

Poster No. 12-  Impact of a Pharmacist Review during Annual Health Checks in HIV patients taking combination antiretroviral therapy - Ivette Aguirre

Poster No. 32 - Use of Concomitant Medications in HIV-1 Infected Patients in a Large Community Practice in Sydney, Australia - Avindra Jayewardene

Poster No. 54 - Predictors of Mortality among HIV Patients on Antiretroviral Treatment in Dr. Sardjito Hospital Yogyakarta - Yurniati

Poster No. 123 -  Creating opportunities for change in HIV policy – a case study of election advocacy in NSW - Dean Price

Poster No. 126 - How do we get the Research Policy-Makers need in HIV and STI’S? - Heather-Marie Schmidt

Oral Poster Session - Theme D.  Facilitator: Duc Nguyen

Oral Poster Session - Theme B.  Facilitator:  John McBride

2Spirits Program

Remembering, Recognising and Responding: 21 years of the Anwernekenhe National HIV Alliance

AFAO Community and Advocacy Hub - Exhibition Hall

10:30am – 11:30am

Morning Tea and Poster Viewing in Exhibition Hall 2

11:30am – 12:00pm

Panel Discussion

Panellists: Dr Roger Wilkie, A/Prof Dr Christopher curlin, and Dr Ralph Montgomery

12:00pm – 1.30pm

Lunch and Poster Viewing in Exhibition Hall 2

1.30pm – 2:30pm

Panel Discussion

Panellists: Dr Roger Wilkie, A/Prof Dr Christopher curlin, and Dr Ralph Montgomery

2:30pm – 3:30pm

Panel Discussion

Panellists: Dr Roger Wilkie, A/Prof Dr Christopher curlin, and Dr Ralph Montgomery

FRIDAY 18 SEPTEMBER

11:00am – 12:30pm

Opening of the Conference/Welcome Address: Welcome, Chair and Welcome to Brisbane

Room: Great Hall 1, Door 6, Mezzanine Level

Dr Eric Hunter, Professor of Pathology & For AIDS Research, Atlanta, USA

11:30am – 12:00pm

Opening of the Conference/Welcome Address: Welcome, Chair and Welcome to Brisbane

Room: Great Hall 1, Door 6, Mezzanine Level

Dr Eric Hunter, Professor of Pathology & For AIDS Research, Atlanta, USA

12.30pm – 1.30pm

Panel Discussion

Panellists: A/Prof Dr Christopher curlin, and Dr Ralph Montgomery

1.30pm – 2:30pm

Panel Discussion

Panellists: Dr Roger Wilkie, A/Prof Dr Christopher curlin, and Dr Ralph Montgomery

2:30pm – 3:30pm

Panel Discussion

Panellists: Dr Roger Wilkie, A/Prof Dr Christopher curlin, and Dr Ralph Montgomery
Friday 18 September

Theme A: Advances in the Understanding of HIV-1 Infections and Therapy

AFAO Community and Advocacy Hub - Exhibition Hall

Afternoon Tea and Poster Viewing in Exhibition Hall 1

Cody Allison
Attrition in Humanized Mice (444)
Sensitises HIV-Infected CD4+ T Cells to Pharmacological Ablation of Cellular In lymph node (LN) (180)
may be associated with CCR5+ pre-Tfh cells
SIV entry into T follicular helper (Tfh) cells

Sydney, NSW, Australia
Conjoint Senior Lecturer, Immunovirology and Applied Medical Research, St Vincent's Hospital;
Dr John Zaunders, Senior Scientist, Centre for Diversity of CCR5+ CD4+ T cells
and its consequences

Theme A - Infection of CCR5+ CD4 T cells

2.30pm – 3.00pm

Vincent Cornelisse, Dr Mark Bloch, Associate Professor Edwina Wright, Department of Medicine (RACP), General Practitioner, Prahran Market Clinic, Melbourne, VIC, Australia
PrEP in primary care
The Australian National PrEP guidelines and its consequences

Theme B - Prevention

2.30pm – 3.00pm

Dr Iryna Zablotska, Dr Professor Robert Grant, Professor of Medicine, The Kirby Institute, UNSW Australia
PrEP use in Australia, now

Theme B - Prevention

2.30pm – 3.00pm

Ahm Haque
Destabilizing the Reverse Transcription Inhibiting HIV-1 Reverse Transcription by Molecular interventions to HIV transmission at the sexual mucosae

Infection and Immunity, University of Melbourne, VIC, Australia
Dr Andrew Harman, Senior Research Fellow, Medicine, The Royal Children's Hospital, VIC, Australia

Theme D - Power, Partnerships and Mobility

3.30pm – 5.00pm

David Fowler
Australian Research Council (ARC) Future Fellowship, Department of Psychology, University of Melbourne, VIC, Australia
In the past, now and in the future

Room:  Great Hall 3, Door 4, Foyer Level

Gilda Tachedjian and Tony Cunningham
Chairs:
Room:  Great Hall 2, Door 8, Mezzanine Level

Silina Motufaga
Importance of measuring capacity in organisational development – designing tools and strategies

Capacity development needs for HIV/SRH providers in the Pacific

Chair: Anthony Lyons
Australian Gay Men (214)

Room:  Great Hall 4, Door 1, Foyer Level

Elan Lazuardi
The Meaning of Outreach Work in Indonesia: The Outreach Workers in HIV&AIDS Prevention Services in Suva, Fiji – A Qualitative Study (395)

Chairs: Graham Brown and Bridget Haire

Room:  Great Hall 4, Door 1, Foyer Level

Venra Grieder
Understanding and expanding the role of professional organisations in Asian-Pacific regions

Understanding and expanding the role of professional organisations in Asia & Pacific – why now and why is this so critical

Chairs: Graham Brown and Bridget Haire

Room:  Great Hall 4, Door 1, Foyer Level

Friday 18 September

Theme A: Advances in the Understanding of HIV-1 Infections and Therapy

AFAO Community and Advocacy Hub - Exhibition Hall

Afternoon Tea and Poster Viewing in Exhibition Hall 1

Cody Allison
Attrition in Humanized Mice (444)
Sensitises HIV-Infected CD4+ T Cells to Pharmacological Ablation of Cellular In lymph node (LN) (180)
may be associated with CCR5+ pre-Tfh cells
SIV entry into T follicular helper (Tfh) cells

Sydney, NSW, Australia
Conjoint Senior Lecturer, Immunovirology and Applied Medical Research, St Vincent's Hospital;
Dr John Zaunders, Senior Scientist, Centre for Diversity of CCR5+ CD4+ T cells
and its consequences

Theme A - Infection of CCR5+ CD4 T cells

2.30pm – 3.00pm

Vincent Cornelisse, Dr Mark Bloch, Associate Professor Edwina Wright, Department of Medicine (RACP), General Practitioner, Prahran Market Clinic, Melbourne, VIC, Australia
PrEP in primary care
The Australian National PrEP guidelines and its consequences

Theme B - Prevention

2.30pm – 3.00pm

Dr Iryna Zablotska, Dr Professor Robert Grant, Professor of Medicine, The Kirby Institute, UNSW Australia
PrEP use in Australia, now

Theme B - Prevention

2.30pm – 3.00pm

Ahm Haque
Destabilizing the Reverse Transcription Inhibiting HIV-1 Reverse Transcription by Molecular interventions to HIV transmission at the sexual mucosae

Infection and Immunity, University of Melbourne, VIC, Australia
Dr Andrew Harman, Senior Research Fellow, Medicine, The Royal Children's Hospital, VIC, Australia

Theme D - Power, Partnerships and Mobility

3.30pm – 5.00pm

David Fowler
Australian Research Council (ARC) Future Fellowship, Department of Psychology, University of Melbourne, VIC, Australia
In the past, now and in the future

Room:  Great Hall 3, Door 4, Foyer Level

Gilda Tachedjian and Tony Cunningham
Chairs:
Room:  Great Hall 2, Door 8, Mezzanine Level

Silina Motufaga
Importance of measuring capacity in organisational development – designing tools and strategies

Capacity development needs for HIV/SRH providers in the Pacific

Chair: Anthony Lyons
Australian Gay Men (214)

Room:  Great Hall 4, Door 1, Foyer Level

Elan Lazuardi
The Meaning of Outreach Work in Indonesia: The Outreach Workers in HIV&AIDS Prevention Services in Suva, Fiji – A Qualitative Study (395)

Chairs: Graham Brown and Bridget Haire

Room:  Great Hall 4, Door 1, Foyer Level

Venra Grieder
Understanding and expanding the role of professional organisations in Asian-Pacific regions

Understanding and expanding the role of professional organisations in Asia & Pacific – why now and why is this so critical

Chairs: Graham Brown and Bridget Haire

Room:  Great Hall 4, Door 1, Foyer Level

View more sessions...